Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy

C M Bloor1, L Nimmo, M D McKirnan

  • 1Department of Pathology, University of California at San Diego, La Jolla, USA.

Insights

Plasminogen activators and inhibitors (PAs/PAIs) gene expression changes early in left ventricular hypertrophy (LVH) and reappear with heart failure, suggesting roles in remodeling and angiogenesis.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Vascular Remodeling

Background:

  • Left ventricular hypertrophy (LVH) involves adaptive coronary vascular remodeling.
  • Plasminogen activators (PAs) and inhibitors (PAIs) are implicated in tissue remodeling and angiogenesis.
  • Understanding PA/PAI roles in early and late LVH is crucial.

Purpose of the Study:

  • Investigate the roles of PAI-1, PAI-2, and urokinase-type plasminogen activator (uPA) in myocyte hypertrophy and angiogenesis during pressure overload-induced LVH.
  • Examine gene expression changes in early and late stages of LVH.

Main Methods:

  • Adult swine underwent aortic constriction to induce LVH.
  • Groups included control, sham-operated, early LVH (8, 24, 72h), and late heart failure LVH.
  • RNA isolation, Northern blotting analyzed PAI-1, PAI-2, and uPA mRNA levels.

Main Results:

  • PAI-1 and PAI-2 mRNA significantly increased at 8 and 24h post-constriction, returning to control levels by 72h, primarily in the endocardium.
  • In late heart failure, PAI-1 and PAI-2 were elevated in both ventricles.
  • Gene expression changes preceded observable morphological changes.

Conclusions:

  • PA and PAI gene expression dynamically change during LVH development, preceding structural alterations.
  • Re-emergence of increased PA/PAI expression in heart failure suggests a role in advanced cardiac remodeling.
  • Regional variations in mRNA levels correlate with altered wall stress, highlighting their importance in angiogenesis during LVH.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...